TTOO OTC
T2 Biosystems, Inc.
1W: +20.0%
1M: -40.0%
3M: -70.0%
YTD: -88.0%
1Y: -95.1%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$7M
-67.8% ▼
5Y CAGR: -7.3%
Gross Profit
-$8M
-800.7% ▼
Operating Income
-$50M
+8.1% ▲
Net Income
-$50M
+19.2% ▲
EPS (Diluted)
$-19.19
+98.4% ▲
EBITDA
-$44M
+20.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $8M | $18M | $28M | $22M | $7M |
| YoY Growth | -20.6% | +117.5% | +54.8% | -20.5% | -67.8% |
| Cost of Revenue | $17M | $21M | $21M | $21M | $15M |
| Gross Profit | -$8M | -$3M | $7M | $1M | -$8M |
| Gross Margin | -101.1% | -17.4% | 26.2% | 5.2% | -113.6% |
| R&D Expenses | $16M | $17M | $22M | $26M | $14M |
| SG&A Expenses | $27M | $21M | $29M | $31M | $25M |
| Operating Expenses | $44M | $38M | $50M | $57M | $41M |
| Operating Income | -$52M | -$41M | -$43M | -$54M | -$50M |
| Operating Margin | -624.6% | -228.1% | -153.2% | -242.3% | -690.4% |
| Interest Expense | $7M | $6M | $8M | $6M | $5M |
| Income Before Tax | -$59M | -$47M | -$49M | -$62M | -$50M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$59M | -$47M | -$49M | -$62M | -$50M |
| Net Margin | -707.9% | -258.1% | -175.5% | -278.0% | -696.2% |
| EPS (Diluted) | $-6934.20 | $-1928.54 | $-1549.82 | $-1222.14 | $-19.19 |
| EBITDA | -$48M | -$37M | -$41M | -$55M | -$44M |
| Shares Outstanding | 9101 | 24266 | 31772 | 51003 | 3M |